Alhemo FDA Approval History
FDA Approved: Yes (First approved December 20, 2024)
Brand name: Alhemo
Generic name: concizumab-mtci
Dosage form: Injection
Company: Novo Nordisk
Treatment for: Hemophilia A with Inhibitors, Hemophilia B with Inhibitors
Alhemo (concizumab-mtci) is a tissue factor pathway inhibitor (TFPI) antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B with inhibitors.
- Alhemo is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
- hemophilia A (congenital factor VIII deficiency) with FVIII inhibitors
- hemophilia B (congenital factor IX deficiency) with FIX inhibitors.
Development timeline for Alhemo
| Date | Article |
|---|---|
| Dec 20, 2024 | Approval FDA Approves Alhemo (concizumab-mtci) to Prevent or Reduce Bleeding Episodes in People with Hemophilia A or B with Inhibitors |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.